Straube Christoph, Scherb Hagen, Gempt Jens, Bette Stefanie, Zimmer Claus, Schmidt-Graf Friederike, Schlegel Jürgen, Meyer Bernhard, Combs Stephanie E
Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München (TUM), Munich, Germany.
Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Munich, Germany.
Radiat Oncol. 2017 Apr 28;12(1):77. doi: 10.1186/s13014-017-0809-9.
Glioblastoma is usually diagnosed around the age of 60-70 years. Patients older than 65 years are frequently described as "elderly". Several trials with monotherapy have established treatment regimens that offer therapies with reduced side effects but reduced efficacy. We analysed the outcome of elderly glioblastoma patients treated at our facility.
We performed a retrospective analysis of 62 consecutive patients older than 65 years treated for a primary glioblastoma at our facility from 2009 to 2015.
Median age was 69.6 years (range 65.1-85.6 years); median OS of the entire cohort was 10.9 months. ECOG, MGMT and extent of resection but not age and the time from surgery to radiotherapy were associated with longer survival. Patients treated with adjuvant chemotherapy had a significantly longer survival (20.5 vs. 7.8 months). Furthermore, salvage therapies were associated with significant improved survival when compared to Best Supportive Care (22.3 vs. 8.8 months).
Also elderly patients are likely to benefit from an aggressive treatment after primary diagnosis of glioblastoma.
胶质母细胞瘤通常在60 - 70岁左右被诊断出来。65岁以上的患者常被描述为“老年患者”。几项单药治疗试验已经确立了一些治疗方案，这些方案副作用较小但疗效也有所降低。我们分析了在我们机构接受治疗的老年胶质母细胞瘤患者的治疗结果。
我们对2009年至2015年期间在我们机构接受原发性胶质母细胞瘤治疗的62例连续65岁以上患者进行了回顾性分析。
中位年龄为69.6岁（范围65.1 - 85.6岁）；整个队列的中位总生存期为10.9个月。东部肿瘤协作组（ECOG）状态、O6 - 甲基鸟嘌呤 - DNA甲基转移酶（MGMT）以及切除范围与较长生存期相关，而年龄和从手术到放疗的时间则与之无关。接受辅助化疗的患者生存期显著更长（20.5个月对7.8个月）。此外，与最佳支持治疗相比，挽救性治疗与生存期显著改善相关（22.3个月对8.8个月）。
胶质母细胞瘤初诊后，老年患者也可能从积极治疗中获益。
